Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-06260414
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PF-06260414 is a selective androgen receptor modulator (SARM) developed by Pfizer for the treatment of muscle weakening conditions such as cachexia. As a SARM, it acts on the androgen receptor to promote anabolic effects on muscle and bone with reduced androgenic activity compared to traditional steroidal androgens. The drug was investigated primarily for its potential in treating conditions associated with muscle loss or weakness, including cachexia and other hormone-related disorders. Clinical studies have shown that it is orally bioavailable and well tolerated in healthy subjects[1][3][5][6]. Development was discontinued after phase I trials[7].
- Other names
- (R)-6-(4-methyl-1,1-dioxido-1,2,6-thiadiazinan-2-yl)isoquinoline-1-carbonitrileUNII 3I487UHH95UNII3I487UHH95UNII-3I487UHH95CAS 1612755-71-1CAS1612755-71-1CAS-1612755-71-1
02
Targets
AR (Adrenergic receptors)
Beyond the preview
Go deeper on PF-06260414.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-06260414.